Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medx Health Corp V.MDX

Alternate Symbol(s):  MDXHF

MedX Health Corp. is a medical device and software company. It develops and manufactures skin-related screening tools and phototherapy devices for pain relief and tissue repair. It focuses on skin health with its SIAscopy on DermSecure telemedicine platform, utilizing its SIAscopy technology. SIAscopy is a medical device technology that is used to scan skin for suspicious moles and lesions and, including DermSecure, its telemedicine software application, and phototherapeutic medical devices, which use light energy in lower-level laser and light-emitting diode to provide treatment of pain and tissue damage in the rehabilitation market. Its products SIAMETRICS, SIMSYS, and MoleMate include hand-held devices that use patented technology utilizing light and its remittance to view up to two millimeters beneath suspicious moles and lesions in a pain free, non-invasive manner. Its SIAscopy on DermSecure telemedicine platform enables the Web-based operation of its SIAscopy scanning technology.


TSXV:MDX - Post by User

Bullboard Posts
Comment by Insightful1on Jan 25, 2020 12:22pm
132 Views
Post# 30598520

RE:RE:RE:RE:RE:Everyone take a breath and relax

RE:RE:RE:RE:RE:Everyone take a breath and relaxI think MedX is in a difficult space as a public company. The larger brokerage firms will not pay attention to MedX as there are no corporate fees to be had and the smaller brokerage firms are bottom feeders and more transactional in nature.They don't have real distribution. So MedX is in investor purgatory but I do not believe for long.  MedX needs more investor eyeballs on the story and it needs a new shareholder audience to move the share price significantly.

So how can MedX achieve this goal?

It needs to attract a few credible microcap managers and in order to do this MedX will need to be cashflow positive. That answers your continous dilution issue as well as your debt repayment issue. I think what you will see over the next few months is MedX rolling out into additional countries as well as making a big inroad into the US market. That will allow MedX to become cashflow positive in short order and have a new US audience to tell the story to.I believe a lot of these initiatives are in place so I am expecting a strong news flow in the first quarter.

Timing on the Brazilian deal? According to the press release the large purchase order came from their Brazilian partners in anticipation of regulatory clearance. This is the largest order in MedX's history so it was MATERIAL and MedX would have had to release this information to shareholders in a timely matter according to OSC/TSX rules. In the press release the Brazilian partners noted they were expecting regulatory clearance shortly and given they are working directly with ANVISA the regulatory body I expect they would have a sense on the timing. They also indicated they had been doing a lot of pre-marketing in Brazil with great success and had developed a stong backlog of orders pending regulatory approval. I think this is just the Brazilian partners getting out ahead of the approval so they can satisfy demand. I do strongly believe tis is just a starting order and Brazil will be a major revenue contributor to MedX this year.

Hope this helps
Bullboard Posts